The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Proseco sorry, autocorrect!
Project,
This could be for the "test to release" (from quarantine I assume).
"Screen4 is a leading provider of COVID-19 testing services and diagnostic testing services to the aviation, petrochemical, occupational health and consumer markets in the UK and across the Middle east and Far East regions. Screen4 is an Approved Provider under the UK Government General testing and 'Test to Release' Scheme in the UK."
As always, news raises lots of questions.
GLA
BB
This is great news for sure. But let’s also not get too excited.
- this is about using the Elisa testing services, it’s not a sale of our manufactured products
- it is specifically for the Mologic Elisa antibody test
- it is not for the airport or quarantine “do you currently have covid” tests
- quantity and value of contract is unknown and antibody tests will likely be lower volume
However, it’s great news and shows the reputation of our Elisa testing service is good. I note that Screen4 work with aviation, maritime and oil and gas employers, so they may be working with them to regularly test their employees before a deployment on a ship, oil rig etc. See their corporate return to work strategy section under their COVID19 services section of the website. It references antibody testing of employees.
Brilliant news
3 yrs minumum
It means a pe for omega will not be one , but higher and if we get a £200 m order then we are heading to a £1 billion capitisiation
£52 per test
Who cares genedrive.dont have that information or provide to shareholders and their so went up 30% yesterday stop trying to deramp
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Contract with Screen4 for COVID-19 antibody laboratory-based testing service
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has signed a contract with Screen4 Ltd ("Screen4") to provide a testing service using the Mologic ELISA1 antibody test for COVID-19 from the Company's in-house testing laboratory in Littleport, Cambridgeshire.
This follows the launch of the COVID-19 antibody testing service, as announced on 26 January 2021. The contract is for an initial term of three years.
Screen4 is a leading provider of COVID-19 testing services and diagnostic testing services to the aviation, petrochemical, occupational health and consumer markets in the UK and across the Middle east and Far East regions. Screen4 is an Approved Provider under the UK Government General testing and 'Test to Release' Scheme in the UK.
Colin King, CEO of Omega, commented: "Following on from setting up and launching our in-house testing service that utilises the Mologic COVID-19 IgG ELISA, I am pleased to be working with Screen4 as our first customer. Screen4 provide a synergistic approach involving health assessment and patient support to their clients."
David Grouse, Managing Director of Screen4, commented: "We are delighted to be involved with Omega Diagnostics on this project. Omega are at the forefront in the development of vital testing technologies to help fight the Covid-19 virus. We will be supporting them through the distribution of their latest product - the COVID-19 ELISA Antibody testing service. The simple, usable nature of this product, particularly with regards to a properly CE marked self-collection sample kit for Home Use, is a major step forward in helping people understand their current status with regards to the virus."